Renalytix plc
("Renalytix" or the "Company")
Result of AGM
LONDON and SALT LAKE, 15 December 2023 - Renalytix (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.
The results of the AGM are detailed below:
| | For | % voted in favour |
| Against | % voted against | Withheld |
| Ordinary resolutions |
| | | | | |
| 1 Accept Financial Statements and Statutory Reports | 40,118,702 | 99.94% | | 24,743 | 0.06% | 67,418 |
| 2 Approve Remuneration Report | 39,959,034 | 99.44% | | 226,856 | 0.56% | 24,973 |
| 3 Re-elect Cathy Coste | 39,058,428 | 97.29% | | 1,086,363 | 2.71% | 66,072 |
| 4 Withdrawn | - | - | | - | - | - |
| 5 Reappoint EY | 39,266,710 | 97.73% | | 910,387 | 2.27% | 33,766 |
| 6 Reappoint PKF Littlejohn LLP as Auditors | 40,142,582 | 99.91% | | 37,614 | 0.09% | 30,667 |
| 7 Authorise Board to Fix Remuneration of Auditors | 40,105,519 | 99.81% | | 77,729 | 0.19% | 27,615 |
| 8 Authorise Issue of Equity | 38,484,392 | 95.78% | | 1,697,234 | 4.22% | 29,237 |
| | | | | | | |
| Special resolutions |
| | | | | |
| 9 Authorise Issue of Equity without Pre-emptive Rights | 38,467,804 | 95.74% | | 1,710,946 | 4.26% | 32,113 |
| 10 Authorise Market Purchase of Ordinary Shares | 39,597,340 | 99.87% | | 51,284 | 0.13% | 562,239 |
| 11 Adoption of new articles | 40,059,859 | 99.74% | | 104,681 | 0.26% | 46,323 |
For further information, please contact:
| Renalytix plc | ||
| James McCullough, CEO | Via Walbrook PR | |
| | | |
| Stifel (Nominated Adviser, Joint Broker) | Tel: 020 7710 7600 | |
| Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea | | |
| | | |
| Investec Bank plc (Joint Broker) | Tel: 020 7597 4000 | |
| Gary Clarence / Shalin Bhamra | | |
| | | |
| Walbrook PR Limited | Tel: 020 7933 8780 or renalytix@walbrookpr.com | |
| Paul McManus / Alice Woodings / Charlotte Edgar | Mob: 07980 541 893 / 07407 804 654 / 07884 664 686 | |
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
